- Details
- Ashish Kamat engages with Kamal Pohar and Kelly Bree on bladder cancer surveillance. They discuss the ongoing debate about the utility of various urinary markers in monitoring bladder cancer. Dr. Pohar mentions his reliance on cytology, while Dr. Bree adds that she uses cytology and occasionally UroVysion FISH for atypical cases, and also blue light cystoscopy despite its challenges. They both hig...
|
- Details
- Ashish Kamat hosts Sima Porten and Roger Li to discuss the management of BCG-unresponsive bladder cancer. They emphasize personalized patient care, starting by understanding patients' goals and risk tolerance. Dr. Porten highlights the importance of discussing radical cystectomy as the gold standard while also considering bladder-preserving treatments depending on the patient's disease characteris...
|
- Details
- Ashish Kamat welcomes Petros Grivas to discuss the current state and future prospects of treating invasive bladder cancer with neoadjuvant chemotherapy or immunotherapy followed by local therapy. Dr. Grivas emphasizes the current standard of care involving neoadjuvant cisplatin-based chemotherapy followed by radical cystectomy or chemoradiation. He highlights promising clinical trials, such as RET...
|
- Details
- Ashish Kamat hosts Paolo Gontero and Michael Cookson to discuss managing high-risk bladder cancer with variant histology. They address the challenges of treating these cases, given the variability in pathology reports and treatment strategies. Dr. Cookson emphasizes treating these patients as high-risk and the importance of proper staging and patient counseling. Dr. Gontero highlights the increase...
|
- Details
- Ashish Kamat is joined by Paramananthan (Param) Mariappan and Sarah Psutka. They discuss managing patients with low-grade intermediate-risk bladder cancer, focusing on treatment, surveillance, and de-escalation strategies. Dr. Psutka emphasizes the complex decision-making process and the need to understand patient priorities. She highlights the importance of discussing the likelihood of recurrence...
|
- Details
- Ashish Kamat and Yair Lotan discuss an innovative AI-based assessment tool presented by Valar Labs, aimed at refining the management of BCG-unresponsive bladder cancer. Dr. Lotan discusses the tool's capability to enhance the precision of prognosis and treatment strategies by analyzing pathologic slides with AI to identify high-risk patients who might not respond well to BCG treatment. This AI alg...
|
- Details
- Pat Hensley hosts a discussion on the role of pelvic lymphadenectomy during radical cystectomy for muscle invasive bladder cancer. Joining him are Dr. Seth Lerner and Dr. Sia (Siamak) Daneshmand, who contribute their insights on the evolution of surgical guidelines and the integration of new biomarkers in the treatment of advanced bladder cancer. Dr. Lerner elaborates on the standard and extended...
|
- Details
- Ashish Kamat discusses the controversial topic of repeat transurethral resection (reTUR) for high-grade non-muscle-invasive bladder cancer with Badrinath (Badri) Konety and Jeremy Teoh. Dr. Konety highlights the importance of surgeon expertise, noting that experience significantly impacts the quality of the initial TUR. Dr. Teoh emphasizes the need for proper training to avoid the necessity of reT...
|
- Details
- Zachary Klaassen discusses the future of bladder cancer treatment with Mark Tyson. They explore the challenges of sequencing treatments for non-muscle invasive bladder cancer, particularly in BCG-naive and unresponsive patients. Dr. Tyson emphasizes the evolving landscape with multiple emerging drugs like Adstiladrin and N-803, which recently received FDA approval. They examine the difficulty in d...
|
- Details
- Sam Chang engages with Ashish Kamat to discuss integrating Adstiladrin into regular clinical practice. During their conversation, Dr. Kamat elaborates on Adstiladrin's journey from clinical trials to its current commercial use, highlighting its 53% complete response rate. They explore the challenges and decisions involved in choosing treatments for BCG-unresponsive non-muscle invasive bladder canc...
|
